Cutting Edge of Brain Natriuretic Peptide (BNP) Research  
— The Diversity of BNP Immunoreactivity and Its Clinical Relevance —

Koichiro Kuwahara, MD, PhD; Yasuaki Nakagawa, MD, PhD; Toshio Nishikimi, MD, PhD

Brain (or B-type natriuretic peptide (BNP)) is a cardiac hormone produced in the heart and an established biochemical marker for heart failure (HF) because the level in plasma increases in proportion to disease severity. Recently, the diversity of BNP molecular forms in the peripheral circulation, which includes mature BNP (BNP1-32) and its metabolites (BNP3-32, BNP4-32, and BNP5-32), was demonstrated. Moreover, studies showed that unprocessed BNP prohormone (proBNP) is also secreted from the heart, and its secretion is increased in patients with HF. Interestingly, BNP1-32, its metabolites, and proBNP are all detected as immunoreactive BNP by the currently available BNP assay system. Current N-terminal proBNP (NT-proBNP) assay systems also can react to both NT-proBNP and proBNP. In addition, the N-terminal region of proBNP and NT-proBNP are often O-glycosylated, which may result in underestimation of total NT-proBNP level, which includes both glycosylated and non-glycosylated NT-proBNP, by the NT-proBNP assay system. More recently, we have shown that miR30-GALNT-dependent O-glycosylation in the N-terminal region of proBNP affects the processing of proBNP and contributes to its secretion from the heart. The level of proBNP relative to BNP (proBNP/BNP ratio) in the coronary sinus is higher in patients with more severe HF. The proBNP/BNP ratio and the deglycosylated NT-proBNP level may be new and clinically useful biomarkers of HF.

Key Words: BNP; Heart failure; NT-proBNP; O-glycosylation; proBNP

The natriuretic peptide family consists of 3 endogenous peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). All 3 peptides were discovered by Kangawa, Matsuo and their colleagues.1-3 Following the discovery of ANP in atrial tissue extract in 1983–1984,1,4 BNP was isolated from porcine brain in 1988.2 Nonetheless, both BNP and ANP are primarily expressed in and secreted from cardiac tissue. They then preferentially bind to natriuretic peptide receptor-A (NPR-A, or guanylyl cyclase-A), which induces generation of the intracellular second messenger cyclic guanosine monophosphate (cGMP) in their target cells. Through its pleiotropic effects, this system plays important roles in the regulation of blood pressure and body fluid volume, leading to the clinical application of both ANP and BNP to the treatment of patients with heart failure (HF). Notably, the plasma BNP level is dramatically increased in proportion to disease severity in patients with HF, and it is currently an established biomarker for heart disease listed in guidelines published worldwide.6,7 Administration of carperitide or nesiritide, which are recombinant ANP and BNP, respectively, is able to ameliorate the hemodynamic conditions and symptoms in patients with HF, despite the high levels of BNP already circulating in these patients. It appears the efficacy of endogenous BNP is lower in these patients than would be expected given the high levels of immunoreactive BNP. This discrepancy reflects the presence of a variety of BNP-related peptides circulating in these patients. In this review, we will discuss the diversity of circulating BNP-related peptides and their clinical relevance.

Does the Currently Available BNP Immunoreactivity System Measure Only BNP1-32?

Plasma BNP levels are increased in proportion to disease severity in patients with HF.8,9 Moreover, it appears they are also increased under other pathological conditions, including myocardial infarction,10 cardiac hypertrophy,11 and pulmonary hypertension.12 With the BNP assay systems (e.g., Shionogi, Biosite) currently in use, BNP is sandwiched by 2 antibodies. One is the capture antibody, which recognizes the C-terminus of BNP, and the other is the detection antibody, which recognizes its ring structure. This assay system thus evaluates BNP levels independently of the length of the N-terminal segment extending from the ring structure. This means the currently available BNP assay also detects proBNP, as well as any truncated BNP metabolites if they are present in the plasma. Indeed, Hawkridge et al13 reported that mass spectrometry after extraction of
plasma using several chromatography techniques detected no mature BNP1-32, arguing that there is no endogenous BNP1-32 in the plasma of patients with severe HF, despite higher plasma immunoreactive BNP levels. A later study using mass spectrometry techniques that carefully dealt with plasma during the extraction process so as not to lose the BNP1-32 activity showed that although BNP1-32 was present, its level was low, and several truncated BNP forms (BNP3-32, BNP4-32, and BNP5-32) were also detected. In addition, Miller et al used a quantitative mass spectrometry immunoassay to show that BNP1-32 levels are low, and that BNP3-32, BNP4-32, and BNP5-32 are also present in plasma from HF patients. They also showed that there are significant relationships between the plasma levels of the truncated

Figure 1. Immunoreactive BNP comprises mature BNP1-32, truncated forms of BNP and proBNP. (A) The currently available BNP assay system uses 2 antibodies, which respectively recognize the ring and C-terminal regions of BNP. Consequently, this system recognizes mature BNP1-32, truncated forms of BNP and proBNP. Our recently developed proBNP-specific assay system uses an antibody common to BNP assays that recognizes the C-terminal region and an antibody that recognizes an area of the N-terminal region that does not contain O-glycosylation sites. This enables us to specifically measure proBNP without the influence of O-glycosylation. (B) Conceptual schemas for an NT-proBNP assay system. The Elecsys I assay system uses an antibody that recognizes NT-proBNP39-50, which contains 2 glycosylation sites, Ser44 and Thr48. The Elecsys II system uses an antibody that recognizes NT-proBNP42-46, which contains one glycosylation site, Ser44. NT-proBNP glycosylated at Ser44 and/or Thr48 is not detected by Elecsys I (Upper), and NT-proBNP glycosylated at Ser44 is not detected by Elecsys II (Lower). BNP, brain (B-type) natriuretic peptide.
BNP forms and levels of clinical BNP. Once in the plasma, depeptidyl peptidase IV (DPP IV) enzymatically cleaves the 2 N-terminal amino acids (serine-proline) from BNP-32 to generate the truncated form, BNP-33,16 the levels of which are increased in patients with HF.17 Moreover, other aminopeptidases in the peripheral circulation may further digest the N-terminal region of BNP-32 and/or BNP-33. These findings indicate that several molecular forms of BNP circulate in the plasma of patients with HF, and the BNP measurement system currently used to measure mature BNP-32 cross-reacts other BNP forms with shorter N-terminal segments, including BNP-33,2 BNP-32, and BNP-31 (Figure 1A).

As mentioned, BNP exerts its physiological effects on target cells via NPR-A-dependent cGMP production. The precise biological activities of the various molecular forms of BNP remain unclear, though BNP-32 and BNP-33 are reported to have similar bioactivity in cardiomyocytes.18 Likewise, the ability of recombinant mouse BNP-32 to induce in vitro cGMP production is reportedly similar to that of mouse BNP-33.19 It may be, therefore, that other BNP forms with shorter N-terminal segments have biological activity similar to that of BNP-32.

Presence of the BNP Precursor proBNP in HF Patients

The BNP precursor peptide, proBNP, is thought to be cleaved to BNP-32 and N-terminal (NT)-proBNP within cardiomyocytes, leading to secretion of BNP-32 and NT-proBNP into the peripheral circulation. However, several recent studies demonstrated that a certain amount of proBNP is itself secreted from cardiomyocytes and circulates in human plasma, and that levels of proBNP are increased in HF patients.17,20 We evaluated plasma and tissue levels of proBNP using gel-filtration high-performance liquid chromatography (HPLC) combined with a direct chemiluminescent BNP immunoassay,24 which showed a high and a low molecular weight (LMW) peak of BNP immunoreactivity, corresponding to proBNP and mature BNP, respectively. We therefore developed a proBNP-specific measurement system, which uses 2 antibodies, BC203 (capture antibody) and 18H5 (detection antibody), which respectively recognize the C-terminal and N-terminal (aa13-20) regions of proBNP (Figure 1A).25 Importantly, because the affinities of the signal antibodies in the proBNP and BNP assay systems are the same, we are able to accurately measure the proBNP/BNP ratio in plasma. Using these 2 assay systems, we measured plasma proBNP and BNP in healthy controls and showed that the proBNP/BNP ratio in plasma of healthy controls was approximately 60–70%, indicating that the major molecular form of plasma BNP is proBNP in healthy controls. Levels of both proBNP and mature BNP are markedly elevated in HF patients, and the magnitude of the increase reflects the severity of the patient’s condition.25

Regarding the biological activity of proBNP, Liang et al reported that recombinant proBNP has much less bioactivity than BNP in human endothelial and vascular smooth muscle cells.26 We also found that proBNP is much less able to induce cGMP production than BNP in cardiomyocytes and fibroblasts cultured from neonatal rats.27 Consequently, when biologically less active proBNP is increased in HF patients, it may lead to decompensation because of the attenuated cardioprotective effect, which does not match the full effect estimated from immunoreactive BNP level. Indeed, proBNP is thought to be one of the causes for the “BNP paradox” (i.e., administration of exogenous natriuretic peptide effectively improves hemodynamics and clinical symptoms in patients with HF, despite apparently high levels of circulating BNP).28

Glycosylation of proBNP and NT-proBNP

In 2006, Schellenberger et al29 reported that the N-terminal region of human proBNP is glycosylated (Figure 2). Their Western blot analysis showed that proBNP isolated from the plasma of HF patients migrated as a diffuse band centered around 25 kDa, and that the band was reduced to 12 kDa by treatment with an O-glycosidase. In addition, using tryptic mapping and liquid chromatography-mass spectrometry, they showed that CHO cell-expressed proBNP is an O-linked glycoprotein containing 7 glycosylation sites (Thr36, Ser37, Ser44, Thr48, Ser53, Thr58, and Thr71). Liang et al30 also reported that when plasma samples from HF patients were immunoprecipitated using an antibody against BNP, subsequent Western blot analysis using an antibody against BNP produced both a high molecular weight (HMW) band (20–22 kDa) and a LMW band. Using recombinant BNP as a reference, the LMW band was identified as BNP, and it was suggested that the HMW band is proBNP and represents the larger fraction of the immunoreactive BNP material. This suggests proBNP is the major molecular form in HF patients. After treatment with a deglycosylating enzyme, the HMW band shifted towards the lower molecular weight band about 12 kDa similar to recombinant deglycosylated proBNP, which is consistent with earlier findings and confirms that a substantial amount of human proBNP is O-glycosylated. Using gel-filtration HPLC combined with a direct chemiluminescent immunassay for BNP, we similarly observed that deglycosylation shifts the peak of proBNP immunoreactivity towards a protein with a smaller molecular mass.28

Because the amino acid sequence of the N-terminal region of proBNP is common to NT-proBNP, that peptide is also thought to be glycosylated. In fact, Seferian et al30 reported that deglycosylation shifts the peak of NT-proBNP immunoreactivity towards proteins with smaller molecular masses. From their Western blot analysis, Hammerer-Lercher et al31 reported that after deglycosylation the band corresponding to NT-proBNP from severe HF patients shifts to a lower molecular weight band corresponding to synthetic NT-proBNP. We confirmed those findings using gel-filtration HPLC analysis combined with a chemiluminescent BNP immunoassay.24 It thus appears that substantial amounts of both proBNP and NT-proBNP are O-glycosylated.

Underestimation of Levels of NT-proBNP

In the previously used NT-proBNP assay system (Elecsys proBNP I; Roche Diagnostics), NT-proBNP is sandwiched by 2 antibodies, a capture monoclonal antibody and a signal polyclonal antibody, recognizing NT-proBNP-21 and NT-proBNP-39–50, respectively (Figure 1B).32 NT-proBNP-19–50 contains 2 glycosylation sites at Ser44 and Thr48. Moreover, O-linked oligosaccharide attachment at those sites almost completely blocks antibody binding to the glycosylated peptides.31,33 We therefore evaluated the effect of deglycosylation on measured levels of NT-proBNP using the Elecsys proBNP I assay in HF patients and patients on
Figure 2. Our hypothesis for the regulation of production of BNP and BNP-related molecules. In heart failure, gene expression of BNP and subsequent production of proBNP are increased in the cardiomyocytes. On the other hand, decreased miR-30 facilitates O-glycosylation via increased GALNT1 and 2. Glycosylation-dependent regulation of proBNP processing affects the proBNP/BNP ratio, probably in response to disease severity. In the peripheral circulation, biologically active BNP1-32, the truncated forms of BNP generated by various proteolytic enzymes, and the biological less active proBNP are all measured as immunoreactive BNP by currently available BNP assay system. The currently available NT-proBNP assay system underestimates the total levels of NT-proBNP because the antibody recognizes an epitope in a region containing glycosylation sites, and its binding is blocked by glycosylation. Treatment with a deglycosylation enzyme would enable estimation of the total levels of NT-proBNP, even with the currently available assay system. It should be noted that NT-proBNP assay system also cross-reacts with proBNP, despite its level being much lower than that of NT-proBNP. The precise structure of glycosylated proBNP or NT-proBNP has not yet been resolved. Consequently, this schema shows assumed structures of glycosylated proBNP and NT-proBNP that are consistent with our hypothesis. BNP, brain (B-type) natriuretic peptide.
Diversity of BNP Molecular Forms

hemodialysis for chronic renal failure (CRF). Plasma BNP levels were elevated to 106±92 pg/mL in NYHA class I patients, and were also increased in NYHA classes II and III–IV patients. Plasma levels of nonglycoNT-proBNP (i.e., NT-proBNP before deglycosylation) were also increased in proportion to HF severity, and were 5.6±4.3, 5.6±3.5, and 6.2±3.4-fold higher than the BNP levels in NYHA classes I, II, and III–IV, respectively. On the other hand, levels of glycoNT-proBNP (i.e., NT-proBNP after deglycosylation minus the levels of nonglycoNT-proBNP) were increased to 34.7±27.7, 33.5±16.7, and 30.1±27.1-fold higher than those of BNP in the respective NYHA classes. This suggests the NT-proBNP assay system underestimates the total levels of NT-proBNP in HF patients, which includes nonglycosylated NT-proBNP and various glycosylated NT-proBNP forms. In patients on hemodialysis for CRF, BNP was increased to 367±265 pg/mL before hemodialysis. The level of NT-proBNP was increased to 7,455±58,348 pg/mL, which is approximately 20-fold higher than the BNP level. After deglycosylation treatment, the level of NT-proBNP was increased to 69,122±9,554 pg/mL, approximately 200-fold that of BNP, suggesting that the NT-proBNP level is underestimated to a greater degree in CRF patients than in HF patients.

We also evaluated the currently available Elecsys proBNP II (Roche Diagnostics) NT-proBNP assay system in CRF patients on hemodialysis.4 Elecsys proBNP II uses 2 antibodies, a capture antibody recognizing NT-proBNP bodies, and a detection antibody recognizing NT-proBNP 27-31 and 62-34.6-fold higher than those measured using the currently available assay system, though the clinical significance of measuring deglycosylated NT-proBNP remains to be determined (Figure 2).

It should be noted that the NT-proBNP assay system also cross-reacts with proBNP because of the common structure in their N-terminal regions (Figure 2). Because the plasma level of proBNP is much lower than that of NT-proBNP, the cross-reaction with proBNP in the NT-proBNP assay system may have little influence on the clinical interpretation of the NT-proBNP level.

Regulation of proBNP Processing by O-Glycosylation of Its N-Terminal Region

Numerous studies have reported on the mechanisms by which BNP gene expression is regulated in response to pathological conditions (reviewed in Kuwahara et al). In addition to transcriptional regulation, post-translational regulation was recently shown to be involved in regulating the secretion of unprocessed proBNP and mature BNP. However, the precise molecular mechanism governing post-translational cleavage of proBNP to BNP was not fully elucidated. We recently clarified the significance of O-glycosylation of the N-terminal region of proBNP, which is regulated via the miR-30-GALNTs axis, to proBNP processing (Figure 2). In humans, the N-terminal segment of circulating proBNP is heavily glycosylated. Within the Golgi apparatus of human ventricular myocytes, proBNP is post-translationally glycosylated at 7 sites in the N-terminal region (Thr36, Ser37, Ser44, Thr48, Ser53, Thr58 and Thr71). The glycosylated proBNP is then transported to the trans-Golgi network, where it is enzymatically cleaved to mature BNP and NT-proBNP by furin. Semenov et al reported that O-glycosylation at Thr71 inhibits the cleavage of recombinant human proBNP in HEK293 cells, which suggests O-glycosylation at Thr71 is involved in regulating proBNP processing. On the other hand, another group reported that both wild-type (WT)-proBNP and a proBNP mutant in which Thr71 was substituted by alanine were processed similarly in HL-1 cells, a line of atrial cardiomycocytes. The significance of O-glycosylation of human proBNP to its processing and secretion in the heart thus remains unclear.

To clarify the contribution made by glycosylation in N-terminal proBNP glycosylation to the regulation of proBNP processing and secretion, we examined the levels of human proBNP and BNP in conditioned medium obtained from neonatal rat ventricular myocytes (NRVMs) infected with lentiviral vectors harboring cDNA encoding WT or mutant human proBNP. WT-proBNP had 7 intact O-glycosylation sites, while the mutant proBNPs contained various combinations of ≥1 mutant glycosylation sites that lacked the capacity for O-glycosylation. We measured proBNP and immunoreactive BNP, which means proBNP+ mature BNP. In the conditioned medium as described earlier and calculated the proBNP/BNP ratio as a processing index. In medium conditioned by NRVMs expressing WT-proBNP, the proBNP/BNP ratio was approximately 0.4. This value is compatible with that in medium conditioned by human iPS-cardiomyocytes and also in plasma from the coronary sinus (CS) of HF patients. In medium conditioned by NRVMs expressing the aforementioned proBNP T71A mutant, the proBNP/BNP ratio was significantly lower than was obtained with WT-proBNP, which indicates O-glycosylation at Thr71 plays a key role in the processing of proBNP in ventricular myocytes, and in its subsequent secretion. Moreover, in the nonglyco-proBNP mutant, in which all 7 glycosylation sites were substituted with alanine, the proBNP/BNP ratio was markedly lower than that obtained with the T71A mutant. This suggests glycosylation sites other than Thr71 are also involved in regulating proBNP secretion. Further examination revealed that O-glycosylation at Thr48 also plays a pivotal role in the regulation of proBNP processing independently of Thr71. In addition, we found that O-glycosylation at each of those 2 sites independently and additively inhibits proBNP processing, while glycosylation at the other 5 sites (Thr36, Ser37, Ser44, Ser53, and Thr58) appears to support the inhibitory effect of glycosylation at Thr48 and Thr71, thereby increasing proBNP secretion from ventricular myocytes.

Hypertrophic stimuli increase the proBNP/BNP ratio via glycosylation-dependent regulation of proBNP secretion. The N-acetylgalactosaminyltransferase (GalNac-T; GALNT) family is known to catalyze O-glycosylation and several GALNT family members are expressed in cardiac myocytes. Knocking down GALNT1 or 2 significantly reduces the proBNP/BNP ratio in medium conditioned by NRVMs expressing WT-proBNP. On the other hand, expression of both GALNT1 and 2 in NRVMs is significantly increased by hypertrophic stimuli, and in the failing hearts of rats. These data suggest GALNT-dependent regulation of O-glycosylation is involved in the increased cardiac secre-
tion of proBNP under pathological conditions. We also found that expression of miR-30, a microRNA abundantly expressed in cardiac myocytes, is decreased by hypertrophic stimuli in vitro and in pathologically remodeled hearts in both rodents and humans. 41 Moreover, miR-30 negatively regulates expression of both GALNT1 and 2 in NRVMs and in mouse heart. 32 All these data suggest that the miR30-GALNT1/2 pathway regulates proBNP/BNP ratio via O-glycosylation of proBNP in response to pathological conditions in the heart. Because the bioactivity of proBNP is much less than that of mature BNP, 32,33 increasing the proBNP/BNP ratio under pathological conditions weakens the cardioprotective effect, which then does not match the full effect estimated from the level of immunoreactive BNP. This can lead to decompensation and deterioration in HF (Figure 2).

Clinical Significance of Evaluating BNP-Related Peptides

Vodovar et al 42 recently proposed a new compensatory mechanism in acute decompensated HF (ADHF) patients. They measured the degree of plasma proBNP glycosylation, BNP1-32, and NT-proBNP and showed that decreases in proBNP glycosylation parallel increases in the production of NT-proBNP and BNP1-32. This means that in ADHF patients, the compensatory mechanism to increase proBNP processing involves decreasing the degree of proBNP glycosylation at Thr71.

We evaluated levels of proBNP and BNP in plasma collected from the aortic root (AO) and CS of 53 consecutive patients with chronic HF. 27 We divided these patients into 2 groups based on the median BNP level in the AO (high-BNP group, low-BNP group). The ProBNP/BNP ratio in the CS and CS-AO, which is indicative of the transcardiac BNP production, were both significantly higher in the high-BNP group. In addition, levels of cGMP/logBNP, which reflect the effect of endogenous BNP, were significantly lower in the high-BNP than in the low-BNP group. When the patients were divided into 2 groups based on the median proBNP/BNP ratio, cGMP/log BNP ratios were significantly lower in the high proBNP/BNP group than in the low proBNP/BNP group. This suggests the proBNP/BNP ratio is higher in patients with more severe HF, leading to a relative shortage of effective endogenous natriuretic peptide.

Takahama et al 43 recently investigated the proBNP/BNP ratio in patients with ADHF. They found: (1) a relationship with ADHF severity, (2) changes in the ratio during treatment, and (3) a relationship with cGMP-generating activity. They measured plasma proBNP and BNP (proBNP+mature BNP, or immunoreactive BNP) in ADHF patients on admission, 3 and 7 days after admission, and before discharge. On admission, the proBNP/BNP ratio was higher in patients with severe ADHF than in those with mild ADHF, while the plasma cGMP/total BNP ratio, an index of the biological activity of BNP, was lower. Thus, in patients with mild ADHF, compensation for HF may occur via increased proBNP processing, leading to increases in mature BNP, 32 and activation of the BNP/cGMP cascade. By contrast, this compensatory mechanism may be impaired in patients with severe ADHF.

Earlier, we mentioned that NT-proBNP is glycosylated and described how the currently available NT-proBNP assay system uses an antibody that recognizes the NT-proBNP region containing the glycosylation sites, which leads to underestimation of the true NT-proBNP level. Rosjo et al 44 assessed the influence of glycosylation on the diagnostic and prognostic accuracy of NT-proBNP in patients with acute dyspnea. They evaluated and compared levels of NT-proBNP measured using the Elecsys proBNP II (Roche Diagnostics) with and without deglycosylation. The patients with acute dyspnea (n=309) were divided into HF and non-HF groups. NT-proBNP levels measured in samples pretreated with deglycosylation enzymes were markedly higher than in samples that were not pretreated (untreated NT-proBNP: HF 3.588 ng/L, non-HF 360 ng/L; treated NT-proBNP: HF 7.497 ng/L, non-HF 798 ng/L). During a median follow-up of 816 days, concentrations of both NT-proBNP and total NT-proBNP (i.e., NT-proBNP pretreated with deglycosylation enzymes) were predictive of death, as assessed with Kaplan-Meier plots, but the total NT-proBNP concentration was more closely associated with death during follow-up than the NT-proBNP concentration. The area under the curve to discriminate HF from non-HF with dyspnea was 0.871 (95% CI 0.829–0.907) for untreated total NT-proBNP and 0.852 (0.807–0.907) for untreated NT-proBNP. These data suggested that NT-proBNP after deglycosylation can be a more useful biomarker for HF than is NT-proBNP as currently evaluated. 44 Further testing of the clinical relevance of deglycosylated NT-proBNP in the patients with HF will be necessary, however.

Acknowledgments

We thank Mebae Kobayashi and Yukari Kubo for their excellent assistance with the manuscript.

Funding

This work was supported by grant-in-Aid for Scientific Research from the Japan Society for the promotion of Science 16K09498 (Y.N.), 15K09138 (T.N.), and 17H04174 (K.K.), and Research Grants from the Uehara Memorial Foundation and the Japan Heart Foundation (K.K.).

Disclosures

None.

References

Diversity of BNP Molecular Forms


